Dorsey & Whitney Trust CO LLC Sells 11,504 Shares of Astrazeneca Plc $AZN

Dorsey & Whitney Trust CO LLC trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 33.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,428 shares of the company’s stock after selling 11,504 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Astrazeneca were worth $3,936,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lloyd Advisory Services LLC. acquired a new stake in Astrazeneca in the 4th quarter valued at approximately $35,000. Basepoint Wealth LLC acquired a new stake in Astrazeneca in the 4th quarter valued at approximately $44,000. Nemes Rush Group LLC grew its holdings in Astrazeneca by 162.1% in the 4th quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock valued at $47,000 after buying an additional 167 shares during the last quarter. Bangor Savings Bank grew its holdings in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC acquired a new stake in Astrazeneca in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Astrazeneca in a report on Monday. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $178.87 on Thursday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The firm has a market capitalization of $277.42 billion, a PE ratio of 26.86, a PEG ratio of 1.60 and a beta of 0.25. The business’s 50 day moving average is $190.12 and its 200-day moving average is $185.76. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Sell-side analysts predict that Astrazeneca Plc will post 9.37 earnings per share for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.